Tessera Therapeutics
Donghui Li is an accomplished professional in the biotechnology and genomic research fields, currently serving as Associate Director at Tessera Therapeutics since December 2018, where previous roles included Senior Scientist and Scientist positions. Prior experience includes a Pre Doctoral Fellowship at NYU Langone Health, focusing on natural and engineered genomes, and activities in venture capital through roles at Alpha Bioventure, LLC, and Cedar Holdings. Academic credentials include a PhD in Human Genetics from The Johns Hopkins University and a B.S. in Biochemistry from Purdue University. Donghui Li has contributed significantly to scientific literature, mentored students, and participated in professional scientific discussions internationally.
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.